drugset / Trial / NCT00860353

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551

NCT00860353 ↗

Phase 1 Terminated 90 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to determine how well tolerated and safe AZD2551 is at different dose levels in healthy, non-smoking males. It will also investigate how quickly AZD2551 is absorbed into and cleared by the body

Timeline

Start
2009-02
Primary completion
—
Completion
2009-05

Outcome

Outcome not reported

Stopped (Business): “Due to portfolio and logistical issues, this study will not be re-started at the present time. The study is not being terminated for safety reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2551 Unknown — Oral

Indications

No indication recorded.